Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen

NICE technology appraisals [TA316] Published date:

Enzalutamide is recommended as a possible treatment option for adults with metastatic hormone-relapsed prostate cancer, who have already had treatment with docetaxel-containing chemotherapy.

What does this mean for me?

If you have metastatic hormone-relapsed prostate cancer and have already had treatment with docetaxel-containing chemotherapy, but your disease has progressed, and your doctor thinks that enzalutamide is the right treatment, you should be able to have the treatment on the NHS.

Enzalutamide should be available on the NHS within 3 months of the guidance being issued.

Get involved